The primary endpoint was change in HbA1c after 26 weeks of treatment , and the main objective was to assess the non-inferiority of IDegLira to insulin degludec ( with an upper 95 % CI margin of 03 % ) , and the superiority of IDegLira to liraglutide ( with a lower 95 % CI margin of 0 % ) .